Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: Results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial

American Heart Journal

Volumn 157, Issue 6, 2009, Pages 1035-1041

  Shah, Sanjiv J ^a   Blair, John E A ^a   Filippatos, Gerasimos S ^b   MacArie, Cezar ^c   Ruzyllo, Witold ^d   Korewicki, Jerzy ^d   Bubenek Turconi, Serban I ^e   Ceracchi, Maurizio ^f   Bianchetti, Maria ^f   Carminati, Paolo ^f   Kremastinos, Dimitrios ^b   Grzybowski, Jacek ^d   Valentini, Giovanni ^f   Sabbah, Hani N ^g   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c National Institute of Cardiovascular Disorders   (Romania)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e CC Iliescu Heart Diseases Institute   (Romania)

^f Sigma Tau SpA   (Italy)

^g HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ((2 AMINOETHOXY)IMINO)ANDROSTANE 6,17 DIONE; 3-((2-AMINOETHOXY)IMINO)ANDROSTANE-6,17-DIONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CARDIOVASCULAR AGENT; DRUG DERIVATIVE; ETIOCHOLANOLONE;

ACUTE DISEASE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HEART; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; AGED; CARDIOVASCULAR AGENTS; DIASTOLE; ETIOCHOLANOLONE; FEMALE; HEART; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; SODIUM-POTASSIUM-EXCHANGING ATPASE; STROKE VOLUME;

EID: 67049100043     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.03.007     Document Type: Article

References (32)

1. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G.
2. Gheorghiade M, Filippatos G, De Luca L, et al. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119(12 Suppl 1):S3-S10. (Pubitemid 44755377)
3. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:840-7.
4. Elkayam U, Janmohamed M, Habib M, et al. Vasodilators in the management of acute heart failure. Crit Care Med 2008;36(1 Suppl): S95-S105.
5. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev 2007;12:143-7. (Pubitemid 46916960)
6. Iyengar S, Abraham WT. Diuretics for the treatment of acute decompensated heart failure. Heart Fail Rev 2007;12:125-30. (Pubitemid 46916958)
7. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompen-sated heart failure. J Am Coll Cardiol 2007;49:675-83. (Pubitemid 46205043)
8. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation 2003;108:367-72. (Pubitemid 36899031)
9. Yu CM, Sanderson JE, Marwick TH, et al. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007;49:1903-14. (Pubitemid 46711162)
10. Wang M, Yip G, Yu CM, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005;45: 272-7. (Pubitemid 40094737)
11. Gheorghiade M, Sabbah HN. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes. Am J Cardiol 2007; 99:1A-3A.
12. Mattera GG, Lo Giudice P, Loi FM, et al. Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol 2007;99: 33A-40A.
13. Micheletti R, Palazzo F, Barassi P, et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 2007;99:24A-32A.
14. Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)andros-tane-6, 17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 2002;303:592-600. (Pubitemid 35231230)
15. Rocchetti M, Besana A, Mostacciuolo G, et al. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E, Z)-3-((2-aminoethoxy) imino)androstane-6, 17-dione hydrochloride]. J Pharmacol Exp Ther 2005;313:207-15. (Pubitemid 40411344)
16. Adamson PB, Vanoli E, Mattera GG, et al. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 2003;42:169-73. (Pubitemid 36899667)
17. Sabbah HN, Imai M, Cowart D, et al. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 2007;99:41A-6A.
18. Blair JE, Macarie C, Ruzyllo W, et al. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther 2008;15:231-40.
19. Lang RM, Bierig M, Devereux RB, etal. Recommendations for chamber quantification: a report from the American Society of Echocardio-graphy's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440-63. (Pubitemid 41821197)
20. Rakowski H, Appleton C, Chan KL, et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction byechocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocar-diogr 1996;9:736-60.
21. Waggoner AD, Bierig SM. Tissue Doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 2001;14:1143-52. (Pubitemid 33144379)
22. Najjar SS, Schulman SP, Gerstenblith G, et al. Age and gender affect ventricular-vascular coupling during aerobic exercise. J Am Coll Cardiol 2004;44:611-7. (Pubitemid 39078188)
23. Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992;86: 513-21.
24. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008;51:2276-85.
25. Borlaug BA, Melenovsky V, Redfield MM, et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 2007;50:1570-7. (Pubitemid 47532334)
26. Daggubati RB, Khanal S, Fallahtafti M, et al. Effect of dobutamine stress on left ventricular systolic and diastolic functions in patients with moderate to severe leftventricular dysfunction. J Am Soc Echocardiogr 1998;11:787-91. (Pubitemid 28376388)
27. Krams R, Mc Falls E, van der Giessen WJ, et al. Does intravenous milrinone have a direct effect on diastolic function? Am Heart J 1991; 121(6 Pt 2):1951-5.
28. Monrad ES, Mc Kay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984;70:1030-7. (Pubitemid 15219364)
29. Nagata K, Iwase M, Sobue T, et al. Differential effects of dobutamine and a phosphodiesterase inhibitor on earlydiastolic filling in patients with congestive heart failure. J Am Coll Cardiol 1995;25:295-304.
30. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96:423-6. (Pubitemid 41058875)
31. Pavlopoulos H, Nihoyannopoulos P. Strain and strain rate deforma-tion parameters: from tissue Doppler to 2D speckle tracking. Int J Cardiovasc Imaging 2008;24:479-91.
32. Teske AJ, De Boeck BW, Melman PG, et al. Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking. Cardiovasc Ultrasound 2007;5:27.